Summary
There is evidence to suggest that glutamate and other excitatory amino acids play an important role in the regulation of neuronal excitation. Glutamate receptor stimulation leads to a non-physiological increase of intracellular free Ca2+. Disturbed Ca2+ homeostasis and subsequent radical formation may be decisive factors in the pathogenesis of neurodegenerative diseases.
Decreased glutamatergic activity appears to contribute to paranoid hallucinatory psychosis in schizophrenia and pharmacotoxic psychosis in Parkinson’s disease. It has been suggested that a loss of glutamatergic function causes dopaminergic over-activity. Imbalances of glutamatergic and dopaminergic systems in different brain regions may result in anti-akinetic effects or the occurrence of psychosis. The simplified hypothesis of a glutamatergic- dopaminergic (im)-balance may lead to a better understanding of motor behaviour and psychosis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Benes FM, Davidson J, Bird ED (1986) Quantitative cytoarchitectural studies of the cerebral cortex of schizophrenics. Arch Gen Psychiatry 43: 31–35
Danielczyk W (1973) Die Behandlung von akinetischen Krisen. Med Welt 24: 1278
Deakin JWF, Slater P, Simpson MDC, Gilchrist AC, Skan WJ, Royston MC, Reynolds GP, Cross AJ (1989) Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J Neurochem 52: 1781–1786
Garthwaite G, Garthwaite J (1987) Receptor-linked ionic channels mediate N-methyl-D-aspartate neurotoxicity in rat cerebellar slices. Neurosci Lett 83: 241–246
Gibson GE, Peterson C (1987) Calcium and the aging nervous system. Neurobiol Aging 8: 329–343
Harrison PJ, McLaughlin D, Kerwin RW (1991) Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet i: 450–452
Jakob H, Beckmann H (1986) Prenatal developmental disturbances in the limbic allocortex in schizophrenics. J Neural Transm 65: 303–326
Kerwin RW, Patel S, Meldrum BS, Czudek C, Reynolds GP (1988) Asymmetrical loss of glutamate receptor subtype in left hippocampus in schizophrenia. Lancet i: 583–584
Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmüller B (1980) Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 20: 379–382
Kornhuber J, Mack-Burkhardt F, Riederer P, Hebenstreit GF, Reynolds GP, Andrews HB, Beckmann H (1989) [3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. J Neural Transm 77: 231–236
Kornhuber J, Riederer P, Beckmann H (1990) The dopaminergic and glutamatergic systems in schizophrenia. In: Bunney WE, Hippius H, Laakmann G, Schmauß M (eds) Neuropsychopharmacology. Springer, Berlin Heidelberg New York Tokyo, pp 714–720
Kurumaji A, Ishimaru M, Torn M (1990) Quisqualate receptors in post-mortem brain of chronic schizophrenics. Proc Kyoto: New Trends in Schizophrenia and Mood Disorders Research, p 29
Löschmann PA, Lange KW, Kunow M, Rettig KJ, Jähnig P, Honore T, Turski L, Wachtel H, Jenner P, Marsden CD (1991) Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-Dopa in models of Parkinson’s disease. J Neural Transm [PD-Sect] 3: 203–213
Meldrum B, Garthwaite J (1990) Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 11: 379–387
Nishikawa T, Takashima M, Torn M (1983) Increased 3H-kainic acid binding in the prefrontal cortex in schizophrenia. Neurosci Lett 40: 245–250
Reynolds IR, Miller RJ (1988) Tricyclic antidepressants block N-methyl-D-aspartate receptors: similarities to the action of zinc. Br J Pharmacol 95: 95–102
Riederer P, Berger W (1991) Locomotion and behaviour: the interaction of loops and transmitter. Proc 5th World Congress of Psychiatry, Florence (in press)
Riederer P, Kornhuber J, Gerlach M, Danielczyk W, Youdim MBH (1991) Glutamatergic-dopaminergic imbalance in Parkinson’s disease and paranoid hallucinatory psychosis. Proc Int Workshop on Parkinson’s Disease, Berlin. Medicom Europe BV (in press)
Schwab RS, England AC, Poskanzer DC, Young RR (1969) Amantadine in the treatment of Parkinson’s disease. J Am Med Assoc 208: 1168
Sherman AD, Davidson AT, Baruah S, Hegwood TS, Waziri R (1991) Evidence of glutamatergic deficiency in schizophrenia. Neurosci Lett 121: 77–80
Suga I, Kobayashi T, Ogata H, Toru M (1990) Increased 3H-MK801 binding sites in post-mortem brains of chronic schizophrenic patients. Proc Kyoto: New Trends in Schizophrenia and Mood Disorders Research, p28
Svensson A, Pileblad E, Carlsson M (1991) A comparison between the non-competitive NMDA antagonist dizocilpine (MK-801) and the competitive NMDA antagonist D-CPPene with regard to dopamine turnover and locomotor-stimulatory properties in mice. J Neural Transm [Gen Sect] 85: 117–129
Watkins JC, Kroogsgaard-Larsen P, Honore T (1990) Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists. Trends Pharmacol Sci 11: 25–33
Weissman AD, Casanova MF, Kleinman JE, London ED, DeSouza EB (1991) Selective loss of cerebral cortical sigma, but not PCP binding sites in schizophrenia. Biol Psychiatry 29: 41–54
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer-Verlag
About this paper
Cite this paper
Riederer, P., Lange, K.W., Kornhuber, J., Jellinger, K. (1991). Glutamate receptor antagonism: neurotoxicity, anti-akinetic effects, and psychosis. In: Bönisch, H., Graefe, KH., Langer, S.Z., Schömig, E. (eds) Recent Advances in Neuropharmacology. Journal of Neural Transmission, vol 34. Springer, Vienna. https://doi.org/10.1007/978-3-7091-9175-0_26
Download citation
DOI: https://doi.org/10.1007/978-3-7091-9175-0_26
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-82300-2
Online ISBN: 978-3-7091-9175-0
eBook Packages: Springer Book Archive